Know Cancer

or
forgot password

Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer


OBJECTIVES:

- Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in
patients with resectable non-small cell lung cancer.

- Determine the treatment-related toxicity in patients treated with this therapy.

- Determine the dimensions of the RFA lesion produced by the ablation procedure in these
patients.

OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes
for each tumor immediately followed by tumor resection.

PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of malignant non-small cell lung cancer (NSCLC)

- Intraoperative needle biopsy confirmation allowed

- Resectable disease (stage I or II)

- All tissue to be treated by radiofrequency tumor ablation must be completely
contained within boundaries of planned lung resection

- Medically fit to undergo lung resection

PATIENT CHARACTERISTICS:

Age:

- Over 18

Performance status:

- Not specified

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

Other:

- Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior or concurrent biologic therapy

Chemotherapy:

- No prior or concurrent chemotherapy

Endocrine therapy:

- No prior or concurrent endocrine therapy

Radiotherapy:

- No prior or concurrent radiotherapy

Surgery:

- See Disease Characteristics

Other:

- No other prior therapy for NSCLC

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

Walter J. Scott, MD, FACS

Investigator Role:

Study Chair

Investigator Affiliation:

Fox Chase Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000069389

NCT ID:

NCT00039507

Start Date:

June 2002

Completion Date:

February 2004

Related Keywords:

  • Lung Cancer
  • stage I non-small cell lung cancer
  • stage II non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Fox Chase Cancer CenterPhiladelphia, Pennsylvania  19111